Pacific Edge Limited (PEB.NZ)

0,0900 -0,0030 (-3,23%) Al cierre: 05:00PM NZST

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 114

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Peter Meintjes	Chief Executive Officer	N/A	N/A	N/A
Mr. Grant Gibson	Chief Financial Officer	N/A	N/A	N/A
Mr. Darrell Morgan	Chief Operating Officer	N/A	N/A	N/A
Dr. Justin Harvey	Chief Technology Officer	N/A	N/A	N/A
Prof. Parry Guilford Ph.D.	Chief Scientific Officer & Member of Scientific Advisory Board	134k	N/A	N/A
Mr. Jack Atchason	Senior Vice President of Sales - Pacific Edge Diagnostics USA Limited	N/A	N/A	N/A
Mr. Andrew McIntosh	Chief Digital Officer	N/A	N/A	N/A
Glen Costin	President of Asia Pacific	N/A	N/A	N/A
Dr. Tamer Aboushwareb	Chief Medical Officer	N/A	N/A	N/A
Mr. David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	53k	N/A	1960

Los importes son a partir de 31 de diciembre de 2009 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en NZD.

Descripción

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Gobierno corporativo

El ISS Governance QualityScore de Pacific Edge Limited, a día 1 de mayo de 2024, es 4. Las puntuaciones base son Auditoría: 6; Tablero: 2; Derechos de los accionistas: 7; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.